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Abstract
EMMPRIN’sexpression inmelanomatissuewasreportedto be predictive of poor prognosis. Here wedemonstratethatEMMPRIN
up-regulated VEGF receptor-2 (VEGFR-2) in two different primary melanomacell lines and consequently increased migration and
proliferation of these cells while inhibiting their apoptosis. SiRNA inhibition of VEGFR-2 expression abrogated these EMMPRIN
effects. EMMPRINregulation of VEGFR-2was mediated through the over-expression of HIF-2aanditstranslocationtothenucleus
where it forms heterodimers with HIF-1b. These results were supported by an in vivo correlation between the expression of
EMMPRIN with that of VEGFR-2 in human melanoma tissues as well as with the extent of HIF-2a localization in the nucleus. They
demonstrate a novel mechanism by which EMMPRIN promotes tumor progression through HIF-2a/VEGFR-2 mediated
mechanism, with an autocrine role in melanoma cell malignancy. The inhibition of EMMPRIN in cancer may thus simultaneously
target both the VEGFR-2/VEGF system and the matrix degrading proteases to block tumor cell growth and invasion.
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Introduction
Malignant melanoma is capable of rapid progression and the
prognosis of the advanced stages of the disease is extremely poor.
Angiogenesis represents an essential step in its multistage
progression and antiangiogenic agents are currently tested in
patients with advanced melanoma [1]. A vital role in tumor
angiogenesis is played by the Vascular Endothelial Growth Factor
(VEGF), but the associated expression of both VEGF and its
receptors by most advanced stage melanomas also suggests the
possibility of an autocrine loop within the melanoma cells. This is
supported by the demonstrated ability of VEGF to stimulate
proliferation and migration of these cells [2]. Although two VEGF
receptors are known, VEGF-R1/flt-1 and VEGFR-2/KDR/flk-1,
VEGF was shown to signal mainly through VEGFR-2, which
upon ligand binding becomes tyrosine phosphorylated and
activates multiple signaling networks [3]. In accordance with this,
patients with high VEGFR-2 expression in melanoma lesions were
shown to be more likely to respond to Sorafenib therapy, a multi-
target kinase inhibitor [4]. This is likely due to inhibition of both
angiogenesis and cell proliferation driven by the presence of a
VEGF/VEGFR-2 autocrine loop in tumor cells.
Extracellular MMP inducer (EMMPRIN/CD147), a mem-
brane glycoprotein greatly enriched on the surface of tumor cells is
known to stimulate tumor and neighbouring stromal cells, such as
fibroblasts and endothelial cells, to increase their synthesis of
several MMPs [5,6,7,8,9]. We have shown that EMMPRIN is not
only an MMP inducer but can also increase the urokinase
plasminogen activating system in tumor and endothelial cells
(ECs), further increasing its proteolytic potential [10]. EMMPRIN
is also implicated in lactate efflux, essential for tumor cell invasion,
via its cotransporter MCT4 [11]. Indeed, the conversion of
glucose to lactic acid in the presence of oxygen, generally known as
aerobic glycolysis or Warburg effect, is uniquely observed in
cancer and the excess generation of lactate that accompanies the
Warburg effect needs to be exported from the cell. Elevated
EMMPRIN levels have been correlated with invasion and tumor
progression in numerous malignant tumor models including
melanoma [12,13]. However, conflicting results regarding the
putative involvement of EMMPRIN in the progression of
melanoma were reported showing that EMMPRIN expression
was observed in non invasive malignant melanoma lesions while
both the benign lesions and the most metastatic melanomas were
negative [14].
The role of EMMPRIN in tumor progression has been
attributed mostly to its protease inducing function. However,
Tang et al [15] have recently reported that the up-regulation of
EMMPRIN in MDA-MB231 breast tumor cells can also increase
PLoS ONE | www.plosone.org 1 August 2010 | Volume 5 | Issue 8 | e12265VEGF expression in these cells, which can then act in a paracrine
manner on endothelial cells to promote tumor angiogenesis. Using
two melanoma cell models we show in this study that EMMPRIN
can also regulate VEGFR-2 within melanoma cells through HIF-
2a, suggesting that EMMPRIN can promote melanoma cell
invasion and disease progression by stimulating the VEGF/
VEGFR-2 autocrine loop.
Results
EMMPRIN up-regulates VEGFR-2 expression in primary
melanoma cells
The role of EMMPRIN in the regulation of VEGFR-2
production in melanoma cells was investigated by inhibiting its
expression using RNA interference strategy. EMMPRIN siRNA
transfection of the two melanoma cell lines M10 and WM278
showed a significant reduction in the level of VEGFR-2, as detected
by western blot and immunofluorescence analysis (Fig. 1A and B).
Thisreductionwasalsoobservedatthetranscript level.Theaverage
decrease in VEGFR-2 observed using two different EMMPRIN
siRNA was 35% in M10 cells and 25% in WM278 cells (Fig. 1C).
EMMPRIN down-regulation in melanoma cells was without any
effect on VEGFR-1 expression (data not shown). The effectiveness
of EMMPRIN siRNA treatment was demonstrated by the reduced
EMMPRIN expression inthe twocell lines at both mRNA(by80%)
and protein levels (by 50%) and by the resulting inhibition of both
MMP-2 and uPA, known to be regulated by EMMPRIN, which
were used as positive controls. No detectable effect on TIMP-1
(negative control [16]) expression was observed (Fig. 1).
The regulation of VEGFR-2 by EMMPRIN was also shown by
treating the cells with exogenously added EMMPRIN. EMM-
PRIN contained within membrane vesicles was obtained from
CHO cells previously transfected with EMMPRIN full length
cDNA. Membrane proteins applied at 25 mg/ml was derived from
approximately 25000 CHO-Emp cells. The incubation of M10
and WM278 cells with the EMMPRIN-containing membranes
(designated Emp) induced VEGFR-2 (,2 fold), whereas those
prepared from mock-transfected CHO cells (Ctl) had no effect
(Fig. 1D). This was accompanied by a 3 fold increase in uPA
expression. Thus, endogenous as well exogenously added EMM-
PRIN regulate VEGFR-2 in two different primary melanoma cell
line models, suggesting a more common mechanism not limited to
a specific cell line.
EMMPRIN regulates melanoma cell migration,
proliferation and apoptosis through VEGFR-2
As VEGF/VEGFR-2 system has been implicated in regulation
of melanoma cells migration, proliferation and apoptotic process-
es, the relationship between EMMPRIN regulation of VEGFR-2
and these cellular properties was investigated. Exogenously added
Emp increased cell migration, measured using a modified Boyden
chamber assay, showing a 2 fold increase in M10 and a 1.5 fold
increase in WM278 compared to control cells. EMMPRIN siRNA
reduced cell migration by 66% in M10 and by 50% in WM278
(Fig. 2A). In order to determine if this EMMPRIN’s effect on cell
migration involves VEGFR-2, the expression of VEGFR-2 was
inhibited by siRNA transfection prior to addition of EMMPRIN
(Fig. 2A). The VEGFR-2 siRNA transfection inhibited cell
migration in both cell lines, although the inhibition was somewhat
greater in M10 cells (46%) than in WM278 (28%) (average of two
siRNA). However, the addition of EMMPRIN containing
membranes to these cells did not restore migration implying that
EMMPRIN enhancement of melanoma cell migration requires
VEGFR-2.
EMMPRIN also regulated cell proliferation in a VEGFR-2
dependant manner. Exogenously added EMMPRIN caused a 1.4
fold and 1.3 fold increases in cell proliferation in M10 and
WM278 respectively, but could not restore the reduced prolifer-
ation observed in the VEGFR-2 siRNA inhibited cells (Fig. 2B).
Similar results were obtained using PNNAG proliferation assay
(data not shown).
We next examined the effect of EMMPRIN on the apoptosis of
these melanoma cells. Exogenous EMMPRIN treatment was
shown to induce an anti-apoptotic effect in both M10 and WM278
cells compared to control as is shown by the respective 54% and
30% inhibition in caspase 3/7 activity (Fig. 2C). VEGFR-2 siRNA
transfection increased the level of caspase3/7 activity by a 2 fold
increase (average of two different siRNA) in M10 but weaker
increase was observed in WM278 cells (average 12%). However,
the addition of EMMPRIN to these VEGFR-2 silenced melanoma
cells did not significantly modified caspase 3/7 activity suggesting
an anti-apoptotic effect of EMMPRIN through of VEGFR-2.
These results were confirmed using annexin-V/7-AAD doubling
staining flow cytometry assay (data not shown).
EMMPRIN up-regulates VEGFR-2 via HIF-2a
As hypoxia-inducible factor HIF-2a is a key regulator of
VEGFR-2 gene expression, we sought to determine whether the
increased expression of VEGFR-2 after EMMPRIN treatment
may result from a stimulation of this transcription factor. The data
in Fig. 3A shows that EMMPRIN treatment up-regulated HIF-2a
both at the RNA and protein levels. This increase, already noted
after 15 min at the RNA and 30 min at the protein level, preceded
that of VEGFR-2 (not shown).
As HIF alpha activity is known to necessitate translocation to
the nucleus, we examined the cell distribution of HIF-2a within
M10 melanoma cells treated with EMMPRIN by immunofluo-
rescence. As is shown in Fig. 3B, EMMPRIN treated cells
exhibited a great increase of HIF-2a staining in the cytoplasm with
a number of cells showing its nuclear accumulation, not observed
in control cells. The nuclear localization of HIF-2a was also
confirmed by western blots of subcellular fractions of M10 cells
treated with EMMPRIN similarly to that obtained with 100 mM
deferoxamine (DFO), used as a positive control(Fig. 3B).
We next investigated whether HIF-2a forms nuclear heterodi-
mers with HIF-1b after EMMPRIN treatment in M10 melanoma
cells. To address that, we used two different approaches:
immunoprecipitation and In situ Proximal ligation assay (in situ
PLA) using confocal microscopy which highlights protein/protein
heterodimers in subcellular compartment. Nuclear extracts
immunoprecipitation using HIF-2a antibody followed by western
blot analysis with HIF-1b antibody have shown that HIF-1b co-
immunoprecipitated with HIF-2a in EMMPRIN and DFO
treated cells while it was not detected in control cells. Furthermore,
In situ PLA assay in melanoma cells treated for 4 hours with
EMMPRIN or DFO (used as positive control) have shown nuclear
heterodimers of HIF-2a and HIF-1b not observed in control cells
(Fig. 3C). These results are in favour of HIF-2a/HIF-1b nuclear
heterodimers formation after EMMPRIN treatment.
We next looked at the effect of HIF-2a silencing on EMMPRIN
regulation of VEGFR-2. HIF-2a siRNA transfection of both
melanoma cell lines down-regulated HIF-2a expression at the
mRNA level by ,67% in M10 and 59% in WM278 cells. This
was associated with a decrease in the basal mRNA levels of
VEGFR-2 (60% for M10 and 28% for WM278) compared with
scrambled control siRNA-transfected cells. The addition of
EMMPRIN to the HIF-2a siRNA-treated cells could no longer
up-regulate VEGFR-2 (Fig. 3A). These results suggest that HIF-2a
EMMPRIN Regulates VEGFR-2/HIF2
PLoS ONE | www.plosone.org 2 August 2010 | Volume 5 | Issue 8 | e12265Figure 1. EMMPRIN up-regulates VEGFR-2 expression in primary melanoma cells. A. M10 and WM278 cells were transfected for 24 hours
with two different EMMPRIN siRNA (Ambion siRNA) or their corresponding scrambled control siRNA (Ctl siRNA) at 33 nmol/L concentration. EMMPRIN
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primary melanoma models.
EMMPRIN correlation with VEGFR-2 expression and HIF-
2a nuclear localization in human melanoma tissues
We next examined human melanoma tissues for possible
association between EMMPRIN and VEGFR-2 expression. In a
tumor series from 26 melanoma patients, a strong correlation was
noted between EMMPRIN and VEGFR-2 transcript levels,
measured using qRT-PCR analysis, (Spearman r=0.82 and
r=0.75 for relative expression to the housekeeping gene
transcripts b2 microglobulin and PPIA respectively; both
p,0.05). We found a statistically significant correlation between
the expression of VEGFR-2 in tumor sample and Clark level
and VEGFR-2 protein expression was evaluated by Western blot analysis of 15 mg cell lysates respectively (actin was used as a loading control;
representative blot of 3 independent experiments is shown) and conditioned medium (CM) was harvested for gelatinases and uPA zymographies. B.
Immunofluorescence of M10 cells treated with EMMPRIN siRNA and immunostained for EMMPRIN, VEGFR-2, uPA and TIMP-1. C. QRT-PCR analyses of
EMMPRIN, VEGFR-2 and TIMP-1 showing the mean 6SD of relative expression to PPIA house keeping gene of at least 3 independent experiments. D.
M10 and WM278 cells were incubated with CHO-membranes containing or not EMMPRIN (Ctl and Emp respectively). VEGFR-2 and uPA transcript
levels were quantified by qRT-PCR showing the mean 6SD of relative expression to PPIA house keeping gene of at least 3 independent experiments.
VEGFR-2 protein expression was evaluated by Western blot analysis of 30 mg cell lysates (actin was used as a loading control; representative blot of 3
independent experiments is shown); bars, SD. *, p,0.05.
doi:10.1371/journal.pone.0012265.g001
Figure 2. EMMPRIN regulates melanoma cell migration, proliferation and apoptosis through VEGFR-2. A, Migration. M10 and WM278
cells seeded in 12-well/insert plates were transfected with EMMPRIN, VEGFR-2 siRNA or scrambled siRNA (Ctl siRNA) before treatment for 24 h in
serum-free medium with Emp (25 mg/ml) or with VEGF (200 ng/mL) used as a positive control. After 24 h of incubation, cells were fixed, stained with
Diff Quik and counted under a microscope. Columns, means of three independent experiments carried out in triplicate; bars, SD. *, P,0.05. B,
Proliferation. M10 and WM278 transfected with VEGFR-2 siRNA or scrambled siRNA (Ctl siRNA) were plated onto 96-well plates and treated with
Emp (25 mg/ml) for 48 hours in serum-free medium. The bioreduction of tetrazolium (MTS) was performed for 4 h at 37uC, and cell proliferation was
quantitatively assessed by measuring absorbance at 490 nm. Results are presented as the mean of three independent experiments carried out in
triplicate; bars, SD. *, p,0.05. C, Caspase-3/7 activity. Transfected melanoma cell lines with VEGFR-2 siRNA or scrambled control (Ctl siRNA) were
seeded onto 96- well plates and treated with Emp (25 mg/ml) for 24 hours in serum-free medium. Apo-one homogeneous Caspase 3/7 buffer
containing Z-DEVD-R110 substrate was added to the cells and incubate at room temperature for 4 hours. The caspase-3/7 activity was measured
using spectrofluorometer at 530 and 485 nm (excitation and emission wavelength respectively). The data represent means of at least three different
experiments; bars, 6 SD. * p,0.05.
doi:10.1371/journal.pone.0012265.g002
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between EMMPRIN nor VEGFR-2 and Breslow index, ulceration
of the primary tumor and overall survival. However, conducting
this analysis on a larger series of patient will be required to
establish whether such correlation does exist.
The expression of EMMPRIN, VEGFR-2 and HIF-2a was also
evaluated by immunohistochemical analysis of tumors obtained
from 5 of these melanoma patients chosen on the basis of their
EMMPRIN expression as determined by the qRT-PCR measure-
ments. Fig. 4 shows a representative staining pattern in tumor
tissues of 2 of these patients with low (1 of 2 patients) and high (1 of
3 patients) expression of EMMPRIN. High EMMPRIN levels
seemed to be associated with high VEGFR-2 levels in the same
tumors. Staining of HIF-2a further shows marked HIF-2a nuclear
localization in the higher EMMPRIN expressing tumors, where
more than 80% of stained cells in the low EMMPRIN expressing
tumors had a non-nuclear localization of HIF-2a. These results
support our in vitro data and suggest that EMMPRIN may also
regulate HIF-2a and VEGFR-2 during tumor progression in vivo.
Discussion
EMMPRIN expression in melanoma tissue correlates with tumor
size and staging, and is predictive of poor prognosis [13]. Although
EMMPRIN is mainly known for its proteinase inducing ability, it is
becoming increasingly clear thati th a so t h e rf u n c t i o n sw h i c hm a y
contributetomalignancy.Using twodifferentprimarymelanomacell
lines we demonstrate in this study that EMMPRIN promotes
melanoma cell proliferation and migration and inhibits apoptosis
through the specific up-regulation of VEGFR-2. These results which
Figure 3. EMMPRIN up-regulates VEGFR-2 through HIF-2a stimulation under normoxic conditions. A. Melanoma cells were transfected
with HIF-2a siRNA or scrambled siRNA (Ctl siRNA) before treatment with 25 mg/ml of Emp for 1 h. a) HIF-2a and VEGFR-2 transcripts were quantified by
qRTPCR (columns, means of relative expression to PPIA housekeeping gene of at least three independent experiments; bars, SD. * p,0.05). b) HIF-2a
protein expression was evaluated by Western blotting. Cells were transfected with scrambled siRNA before Emp treatment. Actin was used as a loading
control; representative blot of 3 independent experiments is shown. B. HIF-2a nuclear localization after EMMPRIN stimulation of M10 melanoma cells. a)
Immunofluoresence analysis of HIF-2a. Cells were grown on the glass slide chamber and treated or not with Emp for 4 h before fixation. HIF-2a protein
localization was visualized by confocal microscopy. b) Western blot analysis of the subcellular fractions (cytosoloic (C) and nuclear (N)) of M10 cells
treated or notwith Empor 100 mM deferoxamine (DFO), used as positive control, for 4 h before being harvested. C. HIF-2a forms heterodimerswith HIF-
1b after EMMPRIN stimulation of M10 melanoma cells. a) HIF-2a protein expression was evaluated by Western blotting of the nuclear fraction after
immunoprecipitation with HIF-1b antibody. b) In situ PLA detection of HIF-2a and HIF-1b heterodimers: HIF-1b/HIF-2a heterodimers (red) in nuclei of
M10 melanoma cells after in situ PLA using antibodies against HIF-1b/HIF-2a. M10 cells were treated or not with Emp or 100 mM deferoxamine (DFO),
usedaspositivecontrol,for4 hours.NucleiwerestainedwithDAPI(blue).TheEMMPRINandDFO panelsshowhigh magnificationtoclearlyvisualizethe
PLA spots representing heterodimers.
doi:10.1371/journal.pone.0012265.g003
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EMMPRIN and that of VEGFR-2 in human melanoma tissues
extend on the proposed protease inducing function of EMMPRIN in
tumor invasion and reveal a novel mechanism by which EMMRPIN
participates in tumor cell progression.
EMMPRIN has already been shown to regulate VEGF
expression in both mammary [15] and melanoma [17,18] tumor
cells, evoking a role in tumor angiogenesis. The secreted VEGF is
thought to increase the VEGF pool in the tumor microenviron-
ment and can then act in a paracrine manner on the VEGF
receptors on endothelial cells to promote angiogenesis. However,
the expression of VEGFR-2 on melanoma cells and its up-
regulation by EMMRPIN suggests an autocrine role with
consequences on the malignant properties of the tumor cells
themselves. Indeed, increasing evidence in recent years support
the functional importance of VEGF receptors in cell types other
than endothelial cells [19]. Immunohistochemical studies in
human melanoma demonstrated that VEGFR-2 expression in
the tumor cells was significantly associated with an increased
proliferative rate, as Ki-67 was present in 89% of the 202 vertical
growth phase melanoma studied [20]. These findings, together
with the lack of correlation noted between VEGFR-2 and the
microvascular density in these tumors reinforce the idea that the
role exerted by VEGF/VEGFR-2 in melanoma is primarily
implicated in promoting melanoma cell growth and may be
independent of the development of a tumor related capillary
network [21,22]. The autocrine role of VEGFR-2, also supported
by in vitro studies [23,24] showing that melanoma cells with higher
levels of VEGFR-2 exhibit a greater ability to spontaneously
invade the extracellular matrix [21], suggests that EMMPRIN’s
increase of VEGFR-2 would primarily reflect a role in melanoma
cell proliferation and invasion.
Our data also show that EMMPRIN up-regulated VEGFR-2
via HIF-2a, one of the isoforms of the hypoxia inducible factors
that mediate adaptation to hypoxic stress in rapidly growing tissues
such as tumors. EMMPRIN increased both expression and
nuclear localization of HIF-2a. Indeed, immunohistochemical
analysis of human melanoma tissues has shown that higher
EMMPRIN levels in the tumor cells were associated with a striking
increase in HIF-2a nuclear localization. However, in cultured
melanoma cells, most of the increased HIF-2a remained cytosolic,
suggesting that only a fraction of its nuclear localization is
sufficient to stimulate transcription of VEGFR-2. Indeed, this
nuclear fraction of HIF-2a was found to form heterodimers with
HIF-1b. VEGFR-2 gene was already shown to be regulated in a
HIF-2a specific manner as a result of cooperation between the
ETS-1 transcription factor and HIF-2a, but not HIF-1a, within
the KDR promoter [25]. The fact that, under our experimental
conditions, EMMPRIN induction of VEGFR-2 via HIF-2a occurs
under normoxic conditions is in accord with the demonstrated
higher stability of HIF-2a than HIF-1a at higher oxygen tensions.
This stability was attributed to the cytoplasmic trapping of HIF-2a
which was suggested to protect it from oxygen-dependent protein
degradation under normoxia, and its overexpression and accu-
mulation in the cytoplasm was shown to induce its translocation to
the nucleus to stimulate gene induction [26]. The higher stability
of HIF-2a is thought to contribute to the development of tumor
aggressiveness by inducing the program for a hypoxic phenotype
Figure 4. Immunohistochemical staining of EMMPRIN, VEGFR-2 and HIF-2a in sections of human melanoma tissues. Left,
representative melanoma with lower expression of EMMPRIN. (A) EMMPRIN, (B) VEGFR-2 and (C) HIF-2a staining. Right, representative melanoma
exhibiting strong expression of EMMPRIN. (D) EMMPRIN, (E) VEGFR-2, and (F) HIF-2a staining.
doi:10.1371/journal.pone.0012265.g004
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therefore that by inducing HIF-2a under normal oxygen levels,
EMMRPIN may contribute to the acquisition of a phenotype with
aerobic glycolysis, referred to as the ‘‘Warburg phenomenon’’,
leading to lactate production and acid microenvironment and the
evolution of acid- resistant cell phenotypes with greater tumor
aggressiveness [28]. EMMPRIN was already shown to increase
lactate release and uptake, thus enhancing glycolytic flux only in
cancer cells including melanoma but not in normal fibroblasts
[29].
Little is known at present on the mechanisms by which
EMMPRIN regulates the production of MMPs or its other targets
such as uPA or VEGF. It is conceivable that a common pathway
exists for EMMPRIN regulation of both VEGFR-2 and the matrix
degrading proteases and which would recapitulate clinical findings
in which MMP and uPA expression in tumor tissues often
correlates with that of the VEGF/VEGFR system and tumor
invasiveness. On the basis of our findings that the regulation of
VEGFR-2 by EMMRPIN in melanoma cells is mediated through
HIF-2a, results strengthened by their correlation in human
melanoma tissues, it is tempting to speculate that HIF-2a
represents a central pathway for the increased expression of these
EMMPRIN target genes. Indeed, elevated HIF-2a levels have
already been associated with MT1-MMP, another EMMPRIN
target gene, as well as VEGF and VEGFR-2 [25].
The implication of VEGFR-2 in tumor progression suggests
that its inhibition could be beneficial in the clinical context.
Indeed, the use of VEGFR-2 blocking antibody in experimental
melanoma models significantly inhibited tumor growth [30]. The
inhibition of EMMPRIN in melanoma can represent an
alternative therapeutic strategy as it is expected to inhibit cell
growth and invasion through the simultaneous inhibition of the
VEGFR-2/VEGF system and the matrix degrading proteases and
possibly other tumor promoting HIF-2a targets.
Materials and Methods
Cell Culture
Primary melanoma cell lines WM278 (Wistar Institute) and
M10, both established from patients primary nodular melanoma,
were cultured as previously described. WM278 cell line is
maintained in a 4:1 mixture of MCDB153 (VWR, France) and
Leibovitz’s L-15 (Invitrogen, France), supplemented with 2% Fetal
bovine serum (FBS) and 5 mg/ml insulin (Sigma, France). M10
cells were maintained in RPMI-medium supplemented with 10%
FBS, Hepes 1M, Pyruvate Na, and L-Glutamine (Invitrogen) [31].
Chinese Hamster Ovary (CHO) cells (ATCC, Rockville, MB)
were cultured in DMEM/F12 (Invitrogen) supplemented with
10% FBS and 2 mML-glutamine. CHO cells were transfected
with a plasmid containing or not EMMPRIN full-lengh cDNA as
previously described [21] and stably transfected cells were
designated as CHO-Emp cells and CHO-Mock cells. CHO-
Emp and CHO-Mock membranes were isolated by differential
centrifugation as previously described [32]. The bioactivity of
EMMPRIN-containing membranes was verified by its activity in
stimulating uPA expression in melanoma cells [10]. The
membrane vesicles obtained from the CHO-Emp or CHO-Mock
cells will be referred to as Emp or Ctl respectively throughout.
Small interfering RNA transfection
siRNA for VEGFR-2 (IDs: 220 and 221), HIF-2a (IDs: s4700
and s4699) and EMMPRIN (IDs: 147251 and 215973) or
scrambled siRNA oligos (Ambion/Applied-Biosystems, France)
were transfected into cells by using the Block-iT transfection kit
and Lipofectamine-2000 (Invitrogen). Cells were then incubated
for 24 h before analysis for qRT-PCR, Western Blotting,
migration, apoptosis and proliferation and for a further 24 hours
in serum-free medium for zymographic analysis.
Western Blotting analysis
Western Blots were preformed as described previously [32].
Membranes were immunoblotted with anti-EMMPRIN (HIM6,
BD, Pharmingen), anti-HIF-2a (ep190b, Novus-Biologicals) or
anti-VEGFR-2 (Sc-504, Santa Cruz-biotechnology) antibodies.
Proteins were visualized with ECL reagent (Pierce) and their
relative expression was determined by densitometry using ImageJ
software program and normalized relative to b-actin.
RNA extraction, reverse transcription and Real-Time
quantitative PCR (qRT-PCR)
Total RNA was isolated using Trizol (Invitrogen). cDNA was
synthesized using random hexamers and M-MLV (Invitrogen).
EMMPRIN, VEGFR-2, HIF-2a and TIMP-1 mRNA levels were
measured by qRT-PCR using Perfect MasterMix-Probe (Any-
Genes, France) on LightCycler 2.0 (Roche) according to the
manufacturer’s protocols. The expression levels of interest
transcripts were normalized to the housekeeping PPIA (peptidyl-
prolyl isomerase A) transcripts. Primers and probes (Eurogentec,
Belgium) are available upon request.
Zymographic analysis
Gelatin or casein zymography was performed as described
previously [10]. Serum-free conditioned media were analyzed on
10% SDS-PAGE gels containing either 1 mg/mL gelatin for
gelatinase activity or 2 mg/mL casein (Sigma) and 10 mg/mL
plasminogen (Calbiochem) for uPA activity.
Immunofluorescence, confocal microscopy
Cells previously transfected with EMMPRIN-siRNA were fixed
and incubated with primary anti-VEGFR-2/KDR (Sc-504, Santa
Cruz Biotechnology), anti-EMMPRIN (HIM6, BD-Pharmingen),
anti-uPA (American Diagnostica) and anti-TIMP-1 (Calbiochem)
antibodies. In other experiments cells were treated or not with
Emp (defined in Cell Culture section) were fixed and incubated
with anti-HIF-2a (ep190b, Novus-Biologicals) antibody. After
incubation with the corresponding secondary antibody (Alexa 488
and 594) the slides were examined with a laser-scanning confocal
microscope (Leica Lasertechnik, Heidelberg). In the negative
controls the primary antibody was substituted with PBS.
In situ proximity ligation assay (in situ PLA)
Cells treated with 25 ng/mL Emmprin or 100 mM deferox-
amine (DFO) for 4 hours were immediately fixed; thereafter
subjected to in situ PLA using Duolink Detection kit (Olink
Bioscience, Uppsala, Sweden) according to the manufacturer’s
instructions for Duolink Blocking solution and Detection protocol.
Briefly, slides were blocked, incubated with antibodies directed
against HIF-2a (1:100; ep190b, Novus-Biologicals) and HIF-1a
(1:150; Santa cruz biotechnology) and thereafter incubated with
PLA probes, which are secondary antibodies (anti-mouse and anti-
rabbit) conjugated to unique oligonucleotides. Circularization and
ligation of the oligonucleotides was followed by an amplification
step. The products were detected by a complementary fluores-
cently labelled probe. The heterodimers visualized as bright
fluorescent signals were examined with a laser-scanning confocal
microscope (Leica Lasertechnik, Heidelberg). Representative
results are shown from experiments repeated at least three times.
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In order to analyze HIF-2a nuclear localization, cytosolic and
nuclear fractions were isolated from 80% confluent cells by using
ProteoExtract Subcellular Proteome Extraction Kit (Calbiochem),
based on differential centrifugation in density gradients. The
cytosolic and nuclear fractions were separated by SDS-PAGE and
analyzed by Western blotting with a mouse anti-HIF-2a antibody.
Co-immunoprecipitation assay
Cultures grown in 100 mm dishes (10
6/dish), treated or not
with Emp or DFO, were lysed. The protein lysate was processed
for immunoprecipitation with 1 mg of HIF-1b antibody (Santa
cruz biotechnology). Immunoprecipitates were collected using
Protein G Sepharose (Sigma) and subjected to SDS–PAGE,
followed by transfer to a nitrocellulose membrane and probed with
antibody for the detection of HIF-2a. Assays were repeated three
times and representative results are shown.
Migration assay
The in vitro migration assay was performed using a modified
Boyden chamber [33]. Emp (25 mg/mL) or VEGF (200 ng/mL
positive control) (R&D-Systems) was added to the cells previously
transfected with VEGFR-2-siRNA and seeded on the upper
chamber of the insert. After 24 h of incubation, cells were fixed,
stained with Diff-Quik (Dade Behring, Deerfield, IL), and counted
under a light microscope.
Cell apoptosis and proliferation assays
Cells seeded into 96-well plates and transfected with VEGFR-2
siRNA were treated with 25 mg/ml of Emp prior to active caspase
3/7 detection using the Apo-ONE Homogeneous Caspase-3/7
Assay kit (Promega) according to the manufacturer’s protocol.
Apoptosis was also assessed by measuring membrane redistribu-
tion of phosphatidilserine using an annexin V-FITC apoptosis
detection kit.
Proliferation of WM278 and M10 was measured using the
CellTiter 96 Aqueous Non Radioactive Cell Proliferation Assay
(Promega).
Analysis of human melanoma tissues
Tumor samples were collected from 26 patients with melanoma
with their informed consent. Frozen and formalin-fixed and
paraffin-embedded tissue sections were analysed by both qRT-
PCR and immunohistochemistry respectively. The study was
performed in accordance with the precepts established by the
Helsinki Declaration and approved by the Hopital Saint Louis
Research Ethic Committee (Paris, France). All patients gave a
written consent. All data were analyzed anonymously. Total RNA
was extracted from frozen tissue sections using TRIzol reagent
(Invitrogen). First-strand cDNA was synthesized using the High-
Capacity cDNA Archive Kit (Applied-Biosystems). Transcript
levels were measured in each melanoma tissue by qPCR using
Perfect Master Mix-Probe (AnyGenes, France) on LightCycler 2.0
System (Roche). The expression levels of interesting transcripts
were normalized to the housekeeping b2 microglobulin (B2M) and
PPIA gene transcripts. All experiments were performed in
duplicates and Spearman’s rank correlation was used to evaluate
the association between mRNA levels in melanoma tissues.
Paraffin-embedded sections were stained with anti-EMMPRIN
(HIM6, BD-Pharmingen), anti-VEGFR-2/KDR (MAB3572,
R&D-Systems, Minneapolis, MN) or anti-HIF-2a (ep190b,
Novus-Biologicals) antibodies. Staining was visualized using the
Vectastain Elite universal ABC-kit (Vector Laboratories, Burlin-
game, CA), followed by counterstaining with Mayer’s hematox-
ylin. Three-amino-9-ethyl-carbazole (Sigma-Aldrich, France) was
used as the chromogen.
Statistical analysis
Data are presented as the mean values 6 SD. Mann-Whitney
test was used to evaluate differences between groups. P,0.05 was
accepted as significant. Pairwise associations between the different
markers were assessed by the use of Spearman rank correlation
coefficient. The association between markers and clinical param-
eters was tested by the use ofWilcoxon rank sum test. The
prognostic value of the studied biomarkers was evaluated for
relapse free survival (RFS) and for overall survival (OS). All tests
were 2-sided at a P,0.05 significance level. Analyses were
performed by the use of statistical software (R version 2.4.0; R
Foundation for Statistical Computing, Vienna, Austria).
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